Minerva Neurosciences reported $-7518000 in EBITDA for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Acadia Pharmaceuticals ACAD:US $ -14.32M 28.46M
Adma Biologics ADMA:US $ -13.02M 1.24M
ALKERMES ALKS:US $ -0.27M 23.16M
Arena Pharmaceuticals ARNA:US $ -123.51M 19.9M
AstraZeneca AZN:LN 2784M 588M
Bristol Myers Squibb BMY:US $ 5712M 33M
Eli Lilly And LLY:US $ 2437.5M 639.8M
Esperion Therapeutics ESPR:US $ -55592000 23.21M
GlaxoSmithKline GSK:LN 3660M 1034M
Halozyme Therapeutics HALO:US $ 76.34M 17.51M
Johnson & Johnson JNJ:US $ 8192M 2043M
Kindred Biosciences KIN:US $ -7.33M 0.63M
Marinus Pharmaceuticals MRNS:US $ -19.08M 4.32M
Minerva Neurosciences NERV:US $ -7.52M 1.44M
Neurocrine Biosciences NBIX:US $ 47.3M 23.1M
Novartis NOVN:VX SF 4837M 65M
Novavax NVAX:US $ -302.88M 40.54M
Pfizer PFE:US $ 10235M 2245M
Takeda 4502:JP Y 238074M 153426M
Vanda Pharmaceuticals VNDA:US $ 11.19M 1.89M